Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v3.10.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Current assets    
Cash and cash equivalents $ 153,081 $ 84,043
Marketable securities - available-for-sale debt securities 84,652 124,218
Accounts receivable, net of allowance for doubtful accounts of $0 and $0 2,031 206
Other current assets and prepaid expenses (including current portion of clinical materials) 21,841 21,716
Total current assets 261,605 230,183
Restricted cash 4,163 4,253
Clinical materials 4,205 4,695
Property, plant and equipment, net 38,137 40,679
Intangibles, net 1,515 1,337
Total assets 309,625 281,147
Current liabilities    
Accounts payable 3,907 8,378
Accrued expenses and other accrued liabilities 24,314 27,201
Deferred revenue 1,345 38,735
Total current liabilities 29,566 74,314
Other liabilities, non-current 3,904 3,849
Total liabilities 33,470 78,163
Stockholders' equity    
Common stock - Ordinary shares par value ?0.001, 701,103,126 authorized and 566,496,400 issued and outstanding (2017: 701,103,126 authorized and 562,119,334 issued and outstanding) 939 854
Additional paid in capital 570,355 455,401
Accumulated other comprehensive loss (12,813) (21,641)
Accumulated deficit (282,326) (231,630)
Total stockholders' equity 276,155 202,984
Total liabilities and stockholders' equity $ 309,625 $ 281,147